Literature DB >> 21986391

Sustainability and performance of the National Cancer Institute's Community Clinical Oncology Program.

William R Carpenter1, Alice K Fortune-Greeley, Leah L Zullig, Shoou-Yih Lee, Bryan J Weiner.   

Abstract

INTRODUCTION: The National Cancer Institute's (NCI) Community Clinical Oncology Program (CCOP) contributes one third of NCI treatment trial enrollment ("accrual") and most cancer prevention and control (CP/C) trial enrollment. Prior research indicated that the local clinical environment influenced CCOP accrual performance during the 1990s. As the NCI seeks to improve the operations of the clinical trials system following critical reports by the Institute of Medicine and the NCI Operational Efficiency Working Group, the current relevance of the local environmental context on accrual performance is unknown.
MATERIALS AND METHODS: This longitudinal quasi-experimental study used panel data on 45 CCOPs nationally for years 2000-2007. Multivariable models examine organizational, research network, and environmental factors associated with accrual to treatment trials, CP/C trials, and trials overall.
RESULTS: For total trial accrual and treatment trial accrual, the number of active CCOP physicians and the number of trials were associated with CCOP performance. Factors differ for CP/C trials. CCOPs in areas with fewer medical school-affiliated hospitals had greater treatment trial accrual.
CONCLUSIONS: Findings suggest a shift in the relevance of the clinical environment since the 1990s, as well as changes in CCOP structure associated with accrual performance. Rather than a limited number of physicians being responsible for the preponderance of trial accrual, there is a trend toward accrual among a larger number of physicians each accruing relatively fewer patients to trial. Understanding this dynamic in the context of CCOP efficiency may inform and strengthen CCOP organization and physician practice.
Copyright © 2011 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Year:  2011        PMID: 21986391      PMCID: PMC3253894          DOI: 10.1016/j.cct.2011.09.007

Source DB:  PubMed          Journal:  Contemp Clin Trials        ISSN: 1551-7144            Impact factor:   2.226


  18 in total

1.  Measuring competition in health care markets.

Authors:  L C Baker
Journal:  Health Serv Res       Date:  2001-04       Impact factor: 3.402

2.  Building community capacity to participate in cancer prevention research.

Authors:  Martha M McKinney; Bryan J Weiner; William R Carpenter
Journal:  Cancer Control       Date:  2006-10       Impact factor: 3.302

3.  The effects of managed care and competition on community-based clinical research.

Authors:  William R Carpenter; Bryan J Weiner; Arnold D Kaluzny; Marisa Elena Domino; Shoou-Yih Daniel Lee
Journal:  Med Care       Date:  2006-07       Impact factor: 2.983

4.  NCI, Cooperative Groups gear up for changes in clinical trials system: new policies initiated in response to institute of medicine report.

Authors:  Carrie Printz
Journal:  Cancer       Date:  2011-05-15       Impact factor: 6.860

5.  The relationship of membership in research networks to compliance with treatment guidelines for early-stage breast cancer.

Authors:  Linda Laliberte; Mary L Fennell; George Papandonatos
Journal:  Med Care       Date:  2005-05       Impact factor: 2.983

6.  The community clinical oncology program: its effect on clinical practice.

Authors:  R B Warnecke; T P Johnson; A D Kaluzny; L G Ford
Journal:  Jt Comm J Qual Improv       Date:  1995-07

7.  Adapting clinical trials networks to promote cancer prevention and control research.

Authors:  Bryan J Weiner; Martha M McKinney; William R Carpenter
Journal:  Cancer       Date:  2006-01-01       Impact factor: 6.860

8.  The Medicare Modernization Act and reimbursement for outpatient chemotherapy: do patients perceive changes in access to care?

Authors:  Joeëlle Y Friedman; Lesley H Curtis; Bradley G Hammill; Jatinder K Dhillon; Charles H Weaver; Sugata Biswas; Amy P Abernethy; Kevin A Schulman
Journal:  Cancer       Date:  2007-11-15       Impact factor: 6.860

9.  Evaluating organizational design to assure technology transfer: the case of the Community Clinical Oncology Program.

Authors:  A D Kaluzny; T Ricketts; R Warnecke; L Ford; J Morrissey; D Gillings; E J Sondik; H Ozer; J Goldman
Journal:  J Natl Cancer Inst       Date:  1989-11-15       Impact factor: 13.506

10.  Predicting the performance of a strategic alliance: an analysis of the Community Clinical Oncology Program.

Authors:  A D Kaluzny; L M Lacey; R Warnecke; D M Hynes; J Morrissey; L Ford; E Sondik
Journal:  Health Serv Res       Date:  1993-06       Impact factor: 3.402

View more
  14 in total

Review 1.  Adolescent angst: enrollment on clinical trials.

Authors:  Theresa H M Keegan; Helen M Parsons
Journal:  Hematology Am Soc Hematol Educ Program       Date:  2018-11-30

2.  Achieving high cancer control trial enrollment in the community setting: an analysis of the Community Clinical Oncology Program.

Authors:  Sara R Jacobs; Bryan J Weiner; Lori M Minasian; Marjorie J Good
Journal:  Contemp Clin Trials       Date:  2013-01-05       Impact factor: 2.226

3.  Organizational designs for achieving high treatment trial enrollment: a fuzzy-set analysis of the community clinical oncology program.

Authors:  Bryan J Weiner; Sara R Jacobs; Lori M Minasian; Marjorie J Good
Journal:  J Oncol Pract       Date:  2012-05-01       Impact factor: 3.840

4.  Organizational and physician factors associated with patient enrollment in cancer clinical trials.

Authors:  Sara R Jacobs; Bryan J Weiner; Bryce B Reeve; Morris Weinberger; Lori M Minasian; Marjorie J Good
Journal:  Clin Trials       Date:  2014-06-05       Impact factor: 2.486

5.  Effect of state-mandated insurance coverage on accrual to community cancer clinical trials.

Authors:  Shellie D Ellis; William R Carpenter; Lori M Minasian; Bryan J Weiner
Journal:  Contemp Clin Trials       Date:  2012-06-08       Impact factor: 2.226

6.  Low Enrollment of Adolescents and Young Adults Onto Cancer Trials: Insights From the Community Clinical Oncology Program.

Authors:  Michael E Roth; Ann M O'Mara; Nita L Seibel; David S Dickens; Anne-Marie Langevin; Brad H Pollock; David R Freyer
Journal:  J Oncol Pract       Date:  2016-03-29       Impact factor: 3.840

7.  Sustaining Research Networks: the Twenty-Year Experience of the HMO Research Network.

Authors:  John F Steiner; Andrea R Paolino; Ella E Thompson; Eric B Larson
Journal:  EGEMS (Wash DC)       Date:  2014-06-09

8.  Increased clinical trial enrollment among adolescent and young adult cancer patients between 2006 and 2012-2013 in the United States.

Authors:  Helen M Parsons; Dolly C Penn; Qian Li; Rosemary D Cress; Brad H Pollock; Marcio H Malogolowkin; Ted Wun; Theresa H M Keegan
Journal:  Pediatr Blood Cancer       Date:  2018-09-06       Impact factor: 3.838

9.  Lack of timely accrual information in oncology clinical trials: a cross-sectional analysis.

Authors:  Aaron P Mitchell; Bradford R Hirsch; Amy P Abernethy
Journal:  Trials       Date:  2014-03-25       Impact factor: 2.279

10.  Context matters: measuring implementation climate among individuals and groups.

Authors:  Sara R Jacobs; Bryan J Weiner; Alicia C Bunger
Journal:  Implement Sci       Date:  2014-04-17       Impact factor: 7.327

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.